UB-221

UB-221 is a humanized IgG1 monoclonal antibody inhibitor targeting IgE. UB-221 significantly decreases IgE synthesis by stabilization of membrane-bound CD23 on B lymphocytes and inhibits FcԑRI-mediated basophil activation and degranulation. UB-221 reduces IgE level in cynomolgus macaques and human IgE (ε, κ) -transgenic (hIGHE-knockin) mice. UB-221 can be used for asthma and chronic spontaneous urticaria (CSU) research[1].

2755114-30-6

12352203

Others

Others

COVID-19-immunoregulation

Inflammation/Immunology

[1]Kuo BS, et al. IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms. J Clin Invest. 2022 Aug 1;132 (15) :e157765. |[2]Casale TB. Novel biologics for treatment of chronic spontaneous urticaria. J Allergy Clin Immunol. 2022 Dec;150 (6) :1256-1259.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P991592/

Inhibitory Antibodies

No Development Reported